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Abstract: The Ghanaian Paenibacillus sp. DE2SH (GenBank Accession Number: MH091697) is a
prolific producer of potent antiparasitic alkaloids. Further detailed study of the culture broth of
this strain produced the compound Paenidigyamycin G (1), which is a derivative of the known
antiparasitic compound Paenidigyamycin A (2). Compound (1) was isolated on HPLC at tR ≈ 37.5 min
and its structure determined by IR, UV, MS, 1D, and 2D-NMR data. Compound 1 produced weak to
moderate antileishmanial and antitrypanosomal activity when tested against Leishmania donovani
(Laveran and Mesnil) Ross (D10) and Trypanosoma brucei subsp. brucei strain GUTat 3.1 with IC50
= 115.41 and 28.75 µM, respectively. This result is interesting since the parent compound 2 is
known to possess consistent and potent antiparasitic activity. However, 1 displayed a promising
selectivity profile towards T. brucei subsp. brucei due to its relatively low toxicity against normal
mouse macrophages RAW 264.7 cells (SI = 8.70). Given that compound 1 is also the main metabolite
found in the hexane fraction of all extracts produced by Paenibacillus sp. DE2SH when it is co-cultured
with other bacteria strains, it must possess some unique biological functions which should make it an
excellent candidate for further biological activity screening in other bioassays.
Keywords: Paenibacillus; alkaloid; imidazole; antileishmanials; leishmaniasis; antitrypanosomals;
trypanosomiasis
1. Introduction
Schistosomiasis, leishmaniasis, and human African trypanosomiasis (HAT) are common neglected
parasitic infections that affect people in sub-Saharan Africa (SSA) and together produce a huge disease
burden in the region [1–3]. It is estimated that for schistosomiasis alone, over 200 million infection cases
and 280,000 schistosomiasis-related deaths are recorded yearly, the majority of which can be found in
SSA [4]. Also, the World Health Organization (WHO) comprehensive statistics on leishmaniasis shows
that an estimated 1 million new cases of this infection are recorded each year with significantly rising
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levels of the deadly visceral leishmaniasis [5]. Comparatively, infection figures for HAT in SSA have
dwindled over the past decade but, nevertheless, a lot more needs to be accomplished to prevent a
huge resurgence of the disease and treatment for the millions of people who continue to harbor the
parasite [6].
While these disabling, chronic, and very painful illnesses occur mostly in the settings of extreme
poverty, their troubling socio-economic impacts also remains the case why these poor populations
of SSA may not be able to escape poverty [7,8]. Unfortunately, current available antiparasitc drugs
for the treatment of schistosomiasis, leishmaniasis, and HAT have severe limitations. Factors such as
widespread development of drug resistance, undesirable and sometimes fatal side effects, complicated
and long drug administration procedures, and high toxicity profiles associated with the current drugs
have made them less appreciable for treatment [9–11]. The main goal of most stakeholders, especially
those of endemic countries, is to greatly reduce the disease burden of schistosomiasis, leishmaniasis,
and HAT [12,13]. However, it is evident that without the availability of chemical structure diversity
and effective drugs to treat all developmental stages of these parasitic infections, efforts to reduce the
burden of these diseases will be significantly hampered. It is therefore urgent that new and robust
antiparasitic drugs are continually discovered and developed as part of efforts to control, cure, and
eradicate parasitic neglected tropical diseases.
In recent years, imidazole-associated natural products have gained significant scientific exploration
for possible antiparasitic drug development [14]. The imidazole nucleus represents an important
heterocyclic core in several biologically active compounds [15,16] and has been found to exhibit unique
medicinal properties such as; excellent tissue penetrability and permeability, high bioavailability
and low incidence of adverse toxicity [17]. Imidazole-associated natural products as well as their
synthetic derivatives are known to demonstrate a wide spectrum of biological activities including:
capravirine (antiviral) [17], metronidazole (antimicrobial) [18], futrimazole (antifungal) [19], losartan
(cardiovascular) [20], flumizole (anti-inflammatory) [21], nafimidone (anticonvulsant) [22], cimetidine
(anticancer agents) [23], and paenidigyamycin A (antiparasitic) [24]. Many imidazole-based compounds
have very useful clinical applications. A critical look at the structures of some of the imidazole-based
compounds mentioned herein reveal a wide diversity of structural modifications that can exist on
the imidazole scaffold and how these substitutions are crucial to the medicinal properties and the
biological potency exerted by imidazole compounds.
In the last four years, we have collected several soils and sediments from extreme biodiverse
environments in Ghana, especially, wetlands from the western and Brong Ahafo regions. Several
cultivable microbial strains were isolated from these samples. Initial biological investigation of the
extracts of the strains yielded promising antiparasitic activities. In an earlier report, we described the
detection, isolation, and characterization of Paenidigyamycin A (2) (Figure S12), a potent antiparasitic
imidazole alkaloid from the Ghanaian Paenibacillus sp. DE2SH [24]. Compound 2, a dimer of the
imidazole nucleus was tested against a variety of parasites and was found to consistently exert potent
antileishmanial activity against L. major (IC50 0.75 µM) and L. donovani (IC50 7.02 µM). Compound 2
also exhibited strong antitrypanosomal activity against T. brucei subsp. brucei strain GUTat 3.1 (IC50
0.78 µM).
Herein, we report on the isolation and characterization of 1-acetyl-2,4-dimethyl-3- phenethyl-1H-
imidazol-3-ium or simply Paenidigyamycin G (1) which is a derivative of the imidazole alkaloid
2 (Figure 1). Fractionation of the crude extracts of the Paenibacillus sp. strain DE2SH through
solvent partitioning by a modification of Kupchan’s method [25] gave four fractions; hexane (FH),
dichloromethane (FD), methanol/water (FM), and butanol/water (WB). Chemical profiling of the
Kupchan sub-fractions using high resolution electrospray ionization liquid chromatography mass
spectrometry (HRESI-LC-MS) and nuclear magnetic resonance spectroscopy (NMR) coupled with
phytochemical screening on thin-layer chromatography (TLC) plates using Dragendorff and Ninhydrin
reagents showed the FH to contain an alkaloid which was structurally related to 2. Coincidentally,
this alkaloid was the major metabolite also seen in the FH fractions whenever strain DE2SH was
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co-cultured with other microbial strains. Therefore, the FH fraction was subjected to reverse phase
HPLC which yielded Paenidigyamycin G (1) at a concentration of 1.3 mg/L.
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Figure 1. Structure of Paenidigyamycin G: 1-acetyl-2,4-dimethyl-3-phenethyl-1H-imidazol-3-ium (1) 
and Paenidigyamycin A (2). 
2. Results 
2.1. Sediment Sample Collection Sites 
Details of the soil and sediment sample collection sites and GPS coordinates can be found in an 
article we have already published [24]. 
2.2. Taxonomy of Strain DE2SH 
The taxonomy of the Ghanaian Paenibacillus sp. strain DE2SH (GenBank Accession Number: 
MH091697) has been described in a previous publication [24]. 
2.3. Structure Determination of Paenidigyamycin G (1) 
Compound 1 was obtained by semi-preparative reverse phase HPLC at tR of 37.5 min (Figure 
S1) as a light yellow oil when completely free of solvent. The HRESI-LC-MS of compound 1 gave m/z 
of 243.1565, corresponding to a molecular formula of C15H19N2O+ (Δ = 0.01 and 8 degrees of 
unsaturation). From this ion, a characteristic loss of an acetyl group produced m/z 200.1424 
corresponding to molecular formulas C13H16N2.+ (Δ = 0.01 ppm and 7 degrees of unsaturation). Other 
classical fragmentation patterns leading to different ions can be found in Figure S3. Analysis of the 
1H, 13C, and multiplicity edited pulsed field gradient heteronuclear single quantum coherence 
(gHSQCAD) and several pulsed field gradient 1H-13C heteronuclear multiple bond correlations 
(gHMBCAD) spectra of 1, suggested the presence of 4 quaternary, 6 methine, 2 methylene, and 3 
methyl carbons. The presence of a mono-substituted benzene ring was easily identified by the 
1H-NMR chemical shifts δH 7.09 (2H, m, H-2’, H-6’), 7.20 (1H, m, H-4’), and 7.25 (2H, m, H-3’, H-5’). 
Detailed analysis of the 1H-1H homonuclear correlation spectroscopy (gCOSY) spectrum showed 
correlations H-2’/H-3’ and H-5’/H-6’, which were further corroborated by similar 1H-1H total 
correlation spectroscopy (2D-TOCSY) correlations, including H-2’/H-4’, H-6’/H-4’, H-3’/H-4’, and 
H-5’/H-4’ to fully establish this aromatic spin system. The gHMBCAD correlations C-1’ to H-8, and 
C-1’ to H-9, showed that the aromatic system was attached to an ethyl group with carbon atoms at δC 
47.0 (C-8) and 36.9 (C-9) and δH 4.48 (2H, t, J = 7.2 Hz, H-8) and 2.92 (2H, t, J = 7.2 Hz, H-9), 
respectively. The gCOSY correlations H-8/H-9 and H-8’/H-9’ confirmed this isolated spin system 
with the lower methylene chemical shift carbon δC 36.9 (C-9) attached to the mono-substituted 
benzene ring; while the higher methylene chemical shift carbon δC 47.0 (C-8) was attached to a 
nitrogen of possible heteroaromatic system. Further confirmation of this structure was provided by 
the HRESI-LC-MS data of 1 (Figure S3), which showed a peak at m/z 105.0690 corresponding to 
C8H9+ (Δ = 0.001 ppm and 4 degrees of unsaturation). The presence of the carbons δC 137.3 (C-2), 
122.3 (C-4), 116.5 (C-5), 9.7 (C-6), and 8.2 (C-7) were characteristic and suggested the presence of two 
methyl substituents on an imidazole ring. The gHMBCAD correlations H-5 to C-2, C-4 and C-6, H-6 
to C-4, C-5 and C-2, H-7 to C-4 and C-2, H-8 to C-2 and C-9 further confirmed the attachment of 
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2. Results
2.1. Sediment Sample Collection Sites
Details of the soil and sediment sample collection sites and GPS coordinates can be found in an
article we have already published [24].
2.2. Taxonomy of Strain DE2SH
The taxonomy of the Ghanaian Paenibacillus sp. strain DE2SH (GenBank Accession Number:
MH091697) has been described in a previous publication [24].
2.3. Structure Determination of Paenidigyamycin G (1)
Compound 1 was obtained by semi-preparative reverse phase HPLC at tR of 37.5 min (Figure S1)
as a light yellow oil when completely free of solvent. The HRESI-LC-MS of compound 1 gave m/z of
243.1565, corresponding to a molecular formula of C15H19N2O+ (∆= 0.01 and 8 degrees of unsaturation).
From this ion, a characteristic loss of an acetyl group produced m/z 200.1424 corresponding to molecular
formulas C13H16N2.+ (∆ = 0.01 ppm and 7 degrees of unsaturation). Other classical fragmentation
patterns leading to different ions can be found in Figure S3. Analysis of the 1H, 13C, and multiplicity
edited pulsed field gradient heteronuclear single quantum coherence (gHSQCAD) and several pulsed
field gradient 1H-13C heteronuclear multiple bond correlations (gHMBCAD) spectra of 1, suggested
the presence of 4 quaternary, 6 methine, 2 methylene, and 3 methyl carbons. The presence of a
mono-substituted benzene ring was easily identified by the 1H-NMR chemical shifts δH 7.09 (2H, m,
H-2’, H-6’), 7.20 (1H, m, H-4’), and 7.25 (2H, m, H-3’, H-5’). Detailed analysis of the 1H-1H homonuclear
correlation spectroscopy (gCOSY) spectrum showed correlations H-2’/H-3’ and -5’/H-6’, which
were further corroborated by similar 1H-1H total correlation spectroscopy (2D-TOCSY) correlations,
including H-2’/H-4’, H-6’/H-4’, H-3’/H-4’, and H-5’/H-4’ to fully establish this aro atic spin system.
The gHMBCAD correlations C-1’ to H-8, and C-1’ to H-9, showed that the aromatic system was attached
to an ethyl group with carbon ato s at δC 47.0 (C-8) and 36.9 (C-9) and δH 4.48 (2H, t, J = 7.2 Hz,
H-8) and 2.92 (2H, t, J = 7.2 Hz, H-9), respectively. The gCOSY correlations H-8/H-9 and H-8’/H-9’
confirmed this isolated spin system with the lower methylene chemical shift carbon δC 36.9 (C-9)
attached to the mono-substituted benzene ring; while the higher methylene chemical shift carbon
δC 47.0 (C-8) was attached to a nitrogen of possible heteroaromatic system. Further confirmation of
this structure was provided by the HRESI-LC-MS data of 1 (Figure S3), which sho ed a peak at m/z
105.0690 corresponding to C8H9+ (∆ = 0.001 ppm and 4 degrees of unsaturation). The presence of the
carbons δC 137.3 (C-2), 122.3 (C-4), 116.5 (C-5), 9.7 (C-6), and 8.2 (C-7) were characteristic and suggested
the presence of two ethyl substituents on an imidazole ring. The gHMBCAD correlations H-5 to
C-2, C-4 and C-6, H-6 to C-4, C-5 and C-2, H-7 to C-4 and C-2, H-8 to C-2 and C-9 further confirmed
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the attachment of imidazole nitrogen to a phenethyl moiety and also the positions of attachment
of two methyl carbons to the imidazole ring. Taking the current substructures forward for the full
structure determination, an acetyl moiety was identified with δC 187.5 (C-10) and 25.4 (C-11), which
was confirmed by the gHMBCAD correlation H-11 to C-10.
Due to the lack of clear spin systems within the imidazole backbone, the 1H-1H rotating-frame
Overhauser spectroscopy (ROESY) data was crucial to facilitate the correct placements of substituents
around the imidazole ring. The ROESY correlations used to finalize the structure include: H-5/H-11,
H-8/H-2’, H-6’ and H-9, H-9/H-2’, H-6’ and H-8. These ROESY correlations in addition to all the other
pieces of data facilitated the placement of the acetyl moiety at N-1.
The complete NMR data for Compound 1 is given in Table 1 while the raw data can be found
in the Supplementary Figures S4–11. In Figures 2 and 3, a visual representation of COSY, HMBC,
2D-TOCSY, and ROESY correlations are shown.
Table 1. 1D and 2D-NMR spectroscopic data for compound (1) in CD3OD, in ppm.
# δC mult
δH mult
(J Hz)
1H-1H COSY HMBC TOCSY
1-N
2 137.3, C
3-N
4 116.5, C
5 122.3, CH 6.96, s 6 C-2, C-4, C-6
6 9.7, CH3 1.99, s 5 C-4, C-5, C-2
7 8.2, CH3 1.90, s C-4, C-2
8 47.0, CH2 4.48, t (7.2) 9 C-2, C-9 9
9 36.9, CH2 2.92, t (7.2) 2’, 8 C-2’, C-1’, C-8 8
10 187.5, C
11 25.4, CH3 2.39, s C-10
1’ 138.7, C
2’ 128.7, CH 7.09, m 3’, 9 C-4’, C-6’, C-9 3’
3’ 128.0, CH 7.25, m 2’ C-5’, C-1’ 2’, 6’
4’ 126.0, CH 7.20, m 3’, 2’, 6’
5’ 128.0, CH 7.25, m 2’ C-3’, C-1’ 2’, 6’
6’ 128.7, CH 7.09, m 3’ C-4’, C-2’, C-9 3’
Molbank 2019, 2019, x 4 of 9 
imidazole nitrogen to a phenethyl moiety and also the positions of attachment of two methyl 
carbons to the imidazole ring. Taking the current substructures forward for the full structure 
determination, an acetyl moiety was identified with δC 187.5 (C-10) and 25.4 (C-11), which was 
confirmed by the gHMBCAD correlation H-11 to C-10. 
Due to the lack of clear spin systems within the imidazole backbone, the 1H-1H rotating-frame 
Overhauser spectroscopy (ROESY) data was crucial to facilitate the correct placements of 
substituents around the imidazole ring. The ROESY correlations used to finalize the structure 
include: H-5/H-11, H-8/H-2’, H-6’ and H-9, H-9/H-2’, H-6’ and H-8. These ROESY correlations in 
addition to all the other pieces of data facilitated the placement of the acetyl moiety at N-1. 
The complete NMR data for Compound 1 is given in Table 1 while the raw data can be found in 
the Supplementary Figures S4–11. In Figures 2 and 3, a visual representation of COSY, HMBC, 
2D-TOCSY, and ROESY correlations are shown. 
 
Figure 2. Key COSY (bold lines), 13C-1H HMBC (single arrows), and TOCSY (bold lines) correlations 
for compound 1. 
 
Figure 3. Key ROESY (double arrow) correlations for compound 1. 
Table 1. 1D and 2D-NMR spectroscopic data for compound (1) in CD3OD, in ppm. 
# δC mult δH mult  (J Hz) 
1H-1H COSY HMBC TOCSY 
1-N      
2 137.3, C     
3-N      
4 116.5, C     
5 122.3, CH 6.96, s 6 C-2, C-4, C-6  
6 9.7, CH3 1.99, s 5 C-4, C-5, C-2  
7 8.2, CH3 1.90, s  C-4, C-2  
8 47.0, CH2 4.48, t (7.2) 9 C-2, C-9 9 
9 36.9, CH2 2.92, t (7.2) 2’, 8 C-2’, C-1’, C-8 8 
10 187.5, C     
11 25.4, CH3 2.39, s  C-10  
      
1’ 138.7, C     
Figure 2. Key COSY (bold lines), 13C-1H HMBC (single arrows), and TOCSY (bold lines) correlations
for compound 1.
Molbank 2019, 2019, M1094 5 of 9
Molbank 2019, 2019, x 4 of 9 
imidazole nitrogen to a phenethyl moiety and also the positions of attachment of two methyl 
carbons to the imidazole ring. Taking the current substructures forward for the full structure 
determination, an acetyl moiety was identified with δC 187.5 (C-10) and 25.4 (C-11), which was 
confirmed by the gHMBCAD correlation H-11 to C-10. 
Due to the lack of clear spin systems within the imidazole backbone, the 1H-1H rotating-frame 
Overhauser spectroscopy (ROESY) data was crucial to facilitate the correct placements of 
substituents around the imidazole ring. The ROESY correlations used to finalize the structure 
include: H-5/H-11, H-8/H-2’, H-6’ and H-9, H-9/H-2’, H-6’ and H-8. These ROESY correlations in 
addition to all the other pieces of data facilitated the placement of the acetyl moiety at N-1. 
The complete NMR data for Compound 1 is given in Table 1 while the raw data can be found in 
the Supplementary Figures S4–11. In Figures 2 and 3, a visual representation of COSY, HMBC, 
2D-TOCSY, and ROESY correlations are shown. 
 
Figure 2. Key COSY (bold lines), 13C-1H HMBC (single arrows), and TOCSY (bold lines) correlations 
for compound 1. 
 
Figure 3. Key ROESY (double arrow) correlations for compound 1. 
Table 1. 1D and 2D-NMR spectroscopic data for compound (1) in CD3OD, in ppm. 
# δC mult δH mult  (J Hz) 
1H-1H COSY HMBC TOCSY 
1-N      
2 137.3, C     
3-N      
4 116.5, C     
5 122.3, CH 6.96, s 6 C-2, C-4, C-6  
6 9.7, CH3 1.99, s 5 C-4, C-5, C-2  
7 8.2, CH3 1.90, s  C-4, C-2  
8 47.0, CH2 4.48, t (7.2) 9 C-2, C-9 9 
9 36.9, CH2 2.92, t (7.2) 2’, 8 C-2’, C-1’, C-8 8 
10 187.5, C     
11 25.4, CH3 2.39, s  C-10  
      
1’ 138.7, C     
i . ( l ) l ti f .
Due to the potent antiparasitic activity shown previously by the parent compound
paenidigyamycin A (2), 1 was also tested for antiparasitic activity against trypanosome and leishmania
parasites. However, 1 was found to exhibit moderate to weak antiparasitic activity against these
parasites. For both T. brucei brucei and L. donovani cells, 1 was observed to be far less potent compared
to 2 which demonstrated very potent antitrypanosomal and antileishmanial activities. The laboratory
standards used for the antitrypanosomal and antileishmanial assays were diminazene aceturate
(IC50 1.86 µM) and amphotericin B (IC50 0.33 µM) respectively. However, in the presence of mouse
macrophages RAW 2 4.7 cell lines, compound 1 was found to display relatively low toxicity profile
on T. brucei brucei with selectivity index (SI) of 8.70 (Figure 4). These results suggest that 1 is
relatively non-toxic to normal cells and if found active in other bioassay screens, would exhibit
interesting bioactivity.
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equipped with shielded z-gradients and cooled preamplifiers for 1H and 13C. The 1H and 13C 
chemical shifts were referenced to the solvent signals (δH 3.31 ppm and δC 49.00 ppm in CD3OD). 
High-resolution mass spectrometry data were measured using a ThermoScientific LTQXL-Discovery 
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achieved on-line through a scan of wavelengths from 200 to 400 nm. This system was also used to 
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3. Experimental Section
3.1. General Experimental Procedures
1D and 2D NMR data were recorded on a Bruker AVANCE III HD Prodigy (BRUKER, Sylvenstein,
Germany) at 500 and 125 MHz for 1H and 13C, respectively. This instrument was optimized for 1H
observation with pulsing/decoupling of 13C and 15N, with 2H lock channels equipped with shielded
z-gradients and cooled preamplifiers for 1H and 13C. The 1H and 13C chemical shifts were referenced
to the solvent signals (δH 3.31 ppm and δC 49.00 ppm in CD3OD). High-resolution mass spectrometry
data were measured using a ThermoScientific LTQXL-Discovery Orbitrap (Thermo Scientific, Bremen,
Germany) coupled to an Accela UPLC-DAD system. The following conditions were used for mass
spectrometric analysis: capillary voltage 45 V, capillary temperature 320 ◦C, auxiliary gas flow rate
10–20 arbitrary units, sheath gas flow rate 40–50 arbitrary units, spray voltage 4.5 kV, and mass range
100–2000 amu (maximum resolution 30,000). Semi-preparative HPLC purifications were carried out
using a Phenomenex Luna reverse-phase (C18 250 × 10 mm, L × i.d.) column connected to a Waters
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1525 Binary HPLC pump Chromatograph with a 2998 photodiode array detector (PDA), column heater,
and in-line degasser. Detection was achieved on-line through a scan of wavelengths from 200 to
400 nm. This system was also used to record the UV profile for the compound. IR was measured using
a PerkinElmer FT-IR (UATR Two) spectrometer. All solvents were HPLC grade. Sephadex LH-20 and
HP-20 resin were obtained from Sigma Aldrich (Munich, Germany).
3.2. Isolation and Purification of the Paenibacillus sp. Strain DE2SH
Isolation, purification, identification, and laboratory cultivation of the Ghanaian Paenibacillus sp.
DE2SH were previously described by our group [24].
3.3. Fermentation of Paenibacillus sp. Strain DE2SH
Autoclaved Erlenmeyer flask (250 mL) plugged with non-absorbent cotton wool containing 50 mL
of TSBY (5 g of tryptic soy, 0.3 g of yeast, and 2 g of sucrose) fermentation media in distilled water was
directly inoculated with spores of strain DE2SH and incubated at 28 ◦C at 220 rpm for 3 days. This seed
culture was subsequently used to inoculate nine autoclaved 1 L Erlenmeyer flasks each containing
200 mL TSBY (20 g of tryptic soy, 1 g of yeast, and 6 g of sucrose) fermentation media and plugged
with non-absorbent cotton wool. The 1 L flasks were incubated at 28 ◦C at 220 rpm for 14 days. Two
days before the culture incubation period was complete, 10 g of autoclaved HP-20 resin was added to
each of the flasks under sterile conditions and the flasks were returned back to the incubator.
Extraction and Purification
The Paenibacillus sp. strain DE2SH fermentation broth (1.8 L) was filtered through a piece of glass
wool under suction in a Buchner funnel to separate the supernatant from the mycelia. The supernatant
was extracted with EtOAc and the mycelia and HP-20 resin were placed in a 1 L flask and extracted
sequentially and alternatively with MeOH and CH2Cl2. All extracts were combined and evaporated
under reduced pressure to obtain a total crude extract (4.24 g). The total crude extract was subjected to
a modification of Kupchan’s solvent partitioning process [25] that gave the four fractions FH (1.8 g),
FD (1.1 g), FM (0.55 g), and WB (0.50 g). Phytochemical screening with Ninhydrin and Dragendorff on
TLC plates followed by 1H-NMR and HRESI-LC-MS showed that the FH contains isolable metabolites.
Fraction FH was therefore subjected to semi-preparative HPLC separation and purification using a
Phenomenex Luna C18 column (C18 250 × 10 mm, L × i.d.). Gradients of Solvent A: 20:80 (MeOH:H2O)
and Solvent B: 100% MeOH (100% A to 100% B in 30 min and hold for 30 min) were used as eluents
with column flow rates set at 1.5 mL/min to afford compound 1 (1.3 mg/L, tR = 37.5 min).
3.4. 1-Acetyl-2,4-dimethyl-3-phenethyl-1H-imidazol-3-ium (1)
Pale yellow oil substance; IR (neat) νmax, 3095, 3074, 3062, 3028, 2872, 1710, 1661, 1621, 1435, 1496,
1374, 751, 703 cm−1; UV (H2O:MeOH) λmax 210, 260, 309 nm (Supplementary Figure S2); for 1H and
13C NMR data, see Table 1; Mass spectrometry data is detailed in Supplementary Figure S3.
3.5. Culture of Parasites and Mammalian Cell Lines
Blood stream forms of Trypanosoma brucei subsp. brucei strain GUTat 3.1 were cultivated in vitro
to the logarithm phase using Hirum’s Modified Iscove’s Media (HMI9, Thermo Fisher Scientific)
supplemented with 10% foetal bovine serum (Thermo Fisher Scientific) at 5% CO2 and 37 ◦C. Leishmania
donovani (Laveran and Mesnil) Ross (D10) was cultivated in vitro to the logarithm phase using Medium
199 (M199, Thermo Fisher Scientific) with 10% FBS at 5% CO2 and 37 ◦C. Mouse macrophages (RAW
264.7 cell lines) were cultivated in vitro to the logarithm phase using Dulbecco’s Modified Eagle Media
(DMEM, Thermo Fisher Scientific) with 10% foetal bovine serum at 5% CO2 and 37 ◦C [26].
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3.6. Analysis of Cell Viability
For Trypanosoma brucei subsp. brucei strain GUTat 3.1 and Leishmania donovani (Laveran and
Mesnil) Ross (D10), cells were seeded at a density of 3.0 × 105 cells/mL in 96 well plates at a two-fold
dilution of the compound and incubated for 24 h. Alamar blue dye (resazurin, 10% V/V) was added to
wells and incubated for another 24 h. For mouse macrophages (RAW 264.7), cell lines were plated at a
density of 3.0 × 105 cells/mL for 48 h to allow for sufficient adherence to plates. The compound under
investigation was then added to the cells in a two-fold dilution and incubated for another 24 h. Alamar
blue dye (10% V/V) was added to wells and incubated for another 24 h. All experiments were run in
quadruplicates. Spectrophotometric absorbance was recorded at a wavelength of 570 nm. Diminazene
aceturate and amphotericin B were used as positive antitrypanosomal and antileishmanial control
drugs respectively in the assays.
4. Conclusions
Paenidigyamycin G (1) is one of the imidazole backbone alkaloids produced by the Ghanaian
Paenibacillus sp. DE2SH (GenBank Accession Number: MH091697). This compound is always found
in the hexane fraction-FH after the Kupchan solvent partitioning of crude extracts produced by liquid
broth fermentation of the strain. Interestingly, among all the alkaloids isolated from DE2SH, 1 is
the only compound produced in huge amounts when the strain is co-cultured with other microbes.
The paenidigyamycins showed potent antiparasitic biological activity profiles and hence, the conscious
effort to evaluate the antiparasitic activity of 1 was made. However, 1 exhibited weak to moderate
antileishmanial and antitrypanosomal activity when tested against Leishmania donovani (Laveran
and Mesnil) Ross (D10) and Trypanosoma brucei subsp. brucei strain GUTat 3.1 with IC50 = 115.41
and 28.75 µM, respectively. However, 1 displayed a promising selectivity profile towards T. brucei
subsp. brucei due to its relatively low toxicity against normal mouse macrophages RAW 264.7 cells
(SI = 8.70). The consistency of the production of 1 in liquid mono- and co-cultures presuppose some
important biological functions which makes 1 a great candidate for further testing in order biological
activity screens.
Supplementary Materials: The following are available online, Figure S1–S12: Spectrometry and Spectroscopy data.
Author Contributions: K.K. and H.D. collected mangrove sediments and isolated the strain DE2SH. A.S.C. and
M.C. identified the exact taxonomy of the strain after K.K. isolated DNA and whole genome sequenced the strain.
M.J. and H.D. provided access to facilities for mass spectrometry and data interpretation. K.K. performed chemical
profiling to identify the major metabolites. S.K., G.M.T. and T.M. performed seed culture, large scale culture,
isolation and purification of compound. K.K. measured all NMR, IR and UV, analyzed the results and integration
of data to give the complete structure of the compound. K.K., S.K. and G.M.T. wrote the initial draft of the article
which was edited and finalized by all the authors.
Funding: KK wishes to thank the Centre for African Wetlands (CAW), University of Ghana, for providing seed
funding to enable the collection of soil samples for microbe isolation and a TWAS Research Grant Award_17-512
RG/CHE/AF/AC_G. K.K. is also very grateful to the Cambridge-Africa Partnership for Research Excellence
(CAPREx), which is funded by the Carnegie Corporation of New York, for a Postdoctoral Fellowship. K.K. also
appreciates the Cambridge-Africa ALBORADA Research Fund for support. K.K., H.D. and M.J. are grateful for
this research which is jointly funded by the UK Medical Research Council (MRC) and the UK Department for
International Development (DFID) under the MRC/DFID African Research Leaders Award (MR/S00520X/1). S.K.
wishes to thank the Carnegie BANGA-Africa Project Award for a PhD scholarship and M.T. is grateful for an
MPhil full scholarship from TWAS Research Grant Award_17-512 RG/CHE/AF/AC_G.
Acknowledgments: All the authors extend their gratitude to the Department of Chemistry, UG for providing
NMR facility.
Conflicts of Interest: The authors declare no conflicts of interests.
Molbank 2019, 2019, M1094 8 of 9
References
1. De Vries, H.; Wagelmans, A.P.; Hasker, E.; Lumbala, C.; Lutumba, P.; De Vlas, S.J.; van de Klundert, J.
Forecasting Human African Trypanosomiasis prevalences from population screening data using continuous
time models. PLoS Comput. Biol. 2016, 12, e1005103. [CrossRef] [PubMed]
2. Copeland, N.K.; Aronson, N.E. Leishmaniasis: Treatment updates and clinical practice guidelines review.
Curr. Opin. Infect. Dis. 2015, 28, 426–437. [CrossRef] [PubMed]
3. Colley, D.G.; Bustinduy, A.L.; Secor, W.E.; King, C.H. Human schistosomiasis. Lancet 2014, 383, 2253–2264.
[CrossRef]
4. Rollinson, D.; Knopp, S.; Levitz, S.; Stothard, J.R.; Tchuenté, L.A.T.; Garba, A.; Utzinger, J. Time to set the
agenda for schistosomiasis elimination. Acta Trop. 2013, 128, 423–440. [CrossRef]
5. Burza, S.; Croft, S.L.; Boelaert, M. Leishmaniasis. Lancet 2018, 392, 951–970. [CrossRef]
6. Gaithuma, A.K.; Yamagishi, J.; Martinelli, A.; Hayashida, K.; Kawai, N.; Marsela, M.; Sugimoto, C. A single
test approach for accurate and sensitive detection and taxonomic characterization of trypanosomes by
comprehensive analysis of internal transcribed spacer 1 amplicons. PLoS Negl. Trop. Dis. 2019, 13, e0006842.
[CrossRef]
7. Mitra, A.; Mawson, A. Neglected tropical diseases: Epidemiology and global burden. Trop. Med. Infect. Dis.
2017, 2, 36. [CrossRef]
8. Hotez, P.J.; Kamath, A. Neglected tropical diseases in sub-Saharan Africa: Review of their prevalence,
distribution, and disease burden. PLoS Negl. Trop. Dis. 2009, 3, e412. [CrossRef]
9. Hotez, P.J.; Pecoul, B.; Rijal, S.; Boehme, C.; Aksoy, S.; Malecela, M.; Reeder, J.C. Eliminating the neglected
tropical diseases: Translational science and new technologies. PLoS Negl. Trop. Dis. 2016, 10, e0003895.
[CrossRef]
10. Pink, R.; Hudson, A.; Mouriès, M.A.; Bendig, M. Opportunities and challenges in antiparasitic drug discovery.
Nat. Rev. Drug Discov. 2005, 4, 727–740. [CrossRef]
11. Cheuka, P.; Mayoka, G.; Mutai, P.; Chibale, K. The role of natural products in drug discovery and development
against neglected tropical diseases. Molecules 2017, 22, 58. [CrossRef] [PubMed]
12. Addisu, A.; Adriaensen, W.; Balew, A.; Asfaw, M.; Diro, E.; Djirmay, A.G.; Adugna, A.H. Neglected tropical
diseases and the sustainable development goals: An urgent call for action from the front line. BMJ Glob
Health. 2019, 4, e001334. [CrossRef] [PubMed]
13. Gupta, K.G.; Kumar, V.; Kaur, K. Imidazole containing natural products as antimicrobial agents: A review.
Nat. Prod. J. 2014, 4, 73–81. [CrossRef]
14. Sharma, A.; Kumar, V.; Kharb, R.; Kumar, S.; Sharma, C.P.; Pathak, P.D. Imidazole derivatives as potential
therapeutic agents. Curr. Pharm. Des. 2016, 22, 3265–3301. [CrossRef]
15. Luca, L.D. Naturally occurring and synthetic imidazoles: Their chemistry and their biological activities.
Curr. Med. Chem. 2006, 13, 1–23.
16. Liu, C.; Shi, C.; Mao, F.; Xu, Y.; Liu, J.; Wei, B.; Li, J. Discovery of new imidazole derivatives containing the
2,4-dienone motif with broad-spectrum antifungal and antibacterial activity. Molecules 2014, 19, 15653–15672.
[CrossRef]
17. Li, X.; Zhan, P.; Clercq, D.E.; Liu, X. The HIV-1 non-nucleoside reverse transcriptase inhibitors (Part V*):
Capravirine and its analogues. Curr. Med. Chem. 2012, 19, 6138–6149.
18. Zhang, W.; Shen, X.; Bergman, U.; Wang, Y.; Chen, Y.; Huang, M.; Deng, L. Drug utilisation 90%(DU90%)
profiles of antibiotics in five Chinese children’s hospitals (2002–2006). Int. J. Antimicrob. Agents 2008, 32,
250–255. [CrossRef]
19. Rotta, I.; Ziegelmann, P.K.; Otuki, M.F.; Riveros, B.S.; Bernardo, N.L.; Correr, C.J. Efficacy of topical antifungals
in the treatment of dermatophytosis: A mixed-treatment comparison meta-analysis involving 14 treatments.
JAMA Dermatol. 2013, 149, 341–349. [CrossRef]
20. Gaba, M.; Mohan, C. Development of drugs based on imidazole and benzimidazole bioactive heterocycles:
Recent advances and future directions. Med. Chem. Res. 2016, 25, 173–210. [CrossRef]
21. Abdellatif, K.R.A.; Fadaly, W.A.A. New 1,2-diaryl-4-substituted-benzylidene-5-4H-imidazolone derivatives:
Design, synthesis and biological evaluation as potential anti-inflammatory and analgesic agents. Bioorg.
Chem. 2017, 72, 123–129. [CrossRef] [PubMed]
Molbank 2019, 2019, M1094 9 of 9
22. Acar, M.F.; Sari, S.; Dalkara, S. Synthesis, in vivo anticonvulsant testing, and molecular modeling studies of
new nafimidone derivatives. Drug Dev. Res. 2019, 80, 606–616. [CrossRef] [PubMed]
23. Watts, A.E.; Maruyoshi, K.; Hughes, C.E.; Brown, S.P.; Harris, K.D. Combining the advantages of powder
X-ray diffraction and NMR crystallography in structure determination of the pharmaceutical material
cimetidine hydrochloride. Cryst. Growth Des. 2016, 16, 1798–1804. [CrossRef]
24. Osei, E.; Kwain, S.; Tetevi, M.G.; Anang, K.A.; Owusu, K.B.-A.; Camas, M.; Camas, A.S.; Ohashi, M.;
Alexandru-Crivac, C.-N.; Deng, H.; et al. Paenidigyamycin A, Potent Antiparasitic Imidazole Alkaloid from
the Ghanaian Paenibacillus sp. DE2SH. Mar. Drugs 2019, 17, 9. [CrossRef]
25. Kwain, S.; Tetevi, G.M.; Mensah, T.; Camas, A.S.; Camas, M.; Dofuor, A.K.; Azerigyik, F.A.;
Deng, H.; Jaspars, M.; Kyeremeh, K. Digyaindoleacid A: 2-(1-(4-Hydroxyphenyl)-3-oxobut-1-en-2-yloxy)
-3-(1H-indol-3-yl) propanoic Acid, a Novel Indole Alkaloid. Molbank 2019, 2019, M1080. [CrossRef]
26. Yabu, Y.; Minagawa, N.; Kita, K.; Nagai, K.; Honma, M.; Sakajo, S.; Koide, T.; Ohta, N.; Yoshimoto, A. Oral
and intraperitoneal treatment of Trypanosoma brucei brucei with a combination of ascofuranone and glycerol
in mice. Parasitol. Int. 1998, 47, 131–137. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
